Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: A comparison of efficacy

Vaccine

Volumn 18, Issue 28, 2000, Pages 3266-3271

  Eyles, Jim E ^a   Williamson, E Diane ^b   Spiers, Ian D ^a   Alpar, H Oya ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Biodegradable microparticles; Bubonic plague; Protective immunity; Pulmonary immunization

Indexed keywords

MICROSPHERE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNIZATION; INFECTION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SURVIVAL RATE; YERSINIA PESTIS;

EID: 0034256999     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00128-6     Document Type: Article

References (38)

1. Perry R.D., Fetherston J.D. Yersinia pestis - Etiologic agent of plague. Clin. Microbiol. Rev. 10:1997;35-66.
2. Titball R.W., Leary S.E.C. Plague. Br. Med. Bull. 54:1998;625-634.
3. Andrews G.P., Heath D.G., Anderson G.W. Jr, Welkos S.L., Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect. Immun. 64:1996;2180-2187.
4. Leary S.E.C., Williamson E.D., Griffin K.F., Russell P., Eley S.M., Titball R.W. Active immunisation with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63:1995;2854-2858.
5. Williamson E.D., Eley S.M., Griffin K.F., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immun. Med. Microbiol. 12:1995;223-230.
6. Anderson G.W. Jr, Heath D.G., Bolt C.R., Welkos S.L., Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg. 58:1998;793-799.
7. MacKenzie D. Breathe easy: could a nasal vaccine finally put an end to the black death? New Scientist. 2163:1998;14.
8. Gupta R.K., Chang A.-C., Siber G.R. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev. Biol. Stand. 92:1998;63-78.
9. O'Hagan D.T. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34:1998;305-320.
10. Eyles J.E., Sharp G.J.E., Williamson E.D., Spiers I.D., Alpar H.O. Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis sub-units confers protection from pneumonic plague in the mouse. Vaccine. 16:1998;698-707.
11. Eyles J.E., Spiers I.D., Williamson E.D., Alpar H.O. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis subunit vaccines. Vaccine. 16:1998;2000-2009.
12. Titball R.W., Howells A.M., Oyston P.C.F., Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun. 65:1997;1926-1930.
13. Eyles J.E., Williamson E.D., Spiers I.D., Stagg A.J., Jones S.M., Alpar H.O. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control Release. 63:2000;191-200.
14. Spiers I.D., Alpar H.O., Eyles J.E., Bozkir A., Miller J., Williamson E.D. Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis. J. Pharm. Pharmacol. 51:1999;991-997.
15. Williamson E.D., Eley S.M., Stagg A.J., Green M.G., Russell P., Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine. 15:1997;1079-1084.
16. Glantz S.A. A primer of biostatistics. 1997;McGraw-Hill, New York.
17. O'Hagan D.T., Illum L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Sys. 7:1990;35-98.
18. Eldridge J.H., Staas J.K., Chen D., Marx P.A., Tice T.R., Gilley R.M. New advances in vaccine delivery systems. Semin. Hematol. 30:1993;16-25.
19. Greenway T.E., Eldridge J.H., Ludwig G., Staas J.K., Smith J.F., Gilley R.M., Michalek S.M. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) aerosol challenge with microencapsulated VEE virus vaccine. Vaccine. 16:1998;1314-1323.
20. Eyles J.E., Williamson E.D., Alpar H.O. Intranasal administration of influenza vaccines. Biodrugs. 13:2000;35-59.
21. Hensel A., Lubitz W. Vaccination by aerosols: modulation of clearance mechanisms by the lung. Behring Inst. Mitt. 98:1997;212-219.
22. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 49:1997;1-10.
23. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine. 12:1994;387-400.
24. Bienstock J. The lung as an immunologic organ. Ann. Rev. Med. 35:1984;49-62.
25. Brandtzaeg P., Berstad A.E., Farstad I.N., et al. Mucosal immunity - a major adaptive defence mechanism. Behring Inst. Mitt. 98:1997;1-23.
26. Steinmetz I. Comparative in vivo analysis of IgA and IgG mediated mucosal defense against bacterial pathogens. Behring Inst. Mitt. 98:1997;53-55.
27. Brandenberg P. Immune functions of human nasal mucosa and tonsils in health. Bienstock J. Immunology of the lung and upper respiratory tract. 1984;28-95 McGraw-Hill, New York.
28. Brandtzaeg P. Cells producing immunoglobulins and other immune factors in human nasal mucosa. Protides Biol. Fluids. 32:1985;363-366.
29. Heritage P.L., Underdown B.J., Arsenault A.L., Snider D.P., McDermott M.R. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156:1997;1256-1262.
30. Ridley Lathers D.M., Gill R.F., Montgomery P.C. Inductive pathways leading to rat tear IgA antibody responses. Invest. Ophthalmol. Vis. Sci. 39:1998;1005-1011.
31. Zee T.C., Osebold J.W., Dotson W.M. Antibody responses and interferon titres in the respiratory tracts of mice after aerosolized exposure to influenza virus. Infect. Immun. 25:1979;202-207.
32. Manzanek M.B., Lamm M.E., Lyn D., Portner A., Nedrud J.G. Comparison of IgA verses IgG monoclonal antibodies for passive immunisation of the murine respiratory tract. Virus Res. 23:1992;1-12.
33. El-Baseir M.M., Kellaway I.W. Poly(L-lactic acid) microspheres for pulmonary drug delivery: release kinetics and aerosolization studies. Int. J. Pharm. 175:1998;135-145.
34. Masinde LE, Hickey AJ. Aerosolized suspensions of Poly(L-lactic acid) microspheres, Int. J. Pharm. 1993;100:123-31.
35. Li V.H.K., Robinson J.R., Lee V.H.L. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems. Robinson J.R., Lee V.H.L. Controlled drug delivery: fundamental and applications. 1987;3-94 Dekker, New York.
36. LiCalsi C., Christensen T., Bennett J.V., Phillips E., Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine. 17:1999;1796-1803.
37. Patton J.S. Deep-lung delivery of proteins. Modern Drug Discovery. 5:1998;19-28.
38. Proc. American conference of governmental industrial hygienists. Cincinnati OH, 1993:29.